Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 20/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3151177 | 0.81 | F10 (0.49) | F10 | |
| SCHEMBL3152468 | 0.81 | F10 (0.49) | F10 | |
| SCHEMBL77099 | 0.81 | F10 (0.63) | F10 | |
| SCHEMBL3156667 | 0.81 | F10 (0.45) | F10 | |
| SCHEMBL3155927 | 0.80 | F10 (0.60) | F10 | |
| SCHEMBL3151179 | 0.79 | F10 (0.62) | F10 | |
| SCHEMBL3155707 | 0.79 | F10 (0.62) | F10 | |
| SCHEMBL3155676 | 0.79 | F10 (0.56) | F10 | |
| SCHEMBL7811141 | 0.79 | MAOB (0.46) | F10 | |
| SCHEMBL3155698 | 0.79 | F10 (0.56) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1526132-B1 | Substituted oxazolidinone derivatives and their use as factor xa inhibitors | BAYER IP GMBH (DE) | 2014-03-12 | — | — | EP | disclosed |
| EP-1411932-B1 | SUBSTITUTED OXAZOLIDINONES FOR COMBINATIONAL THERAPY | BAYER SCHERING PHARMA AG (DE) | 2010-02-10 | — | — | EP | disclosed |
| EP-1937271-A1 | MICROANGIOPATHY TREATMENT AND PREVENTION | Bayer HealthCare AG (DE) | 2008-07-02 | — | — | EP | disclosed |
| EP-1933841-A1 | COMBINATION THERAPY COMPRISING SUBSTITUTED OXAZOLIDINONES FOR THE PREVENTION AND TREATMENT OF CEREBRAL CIRCULATORY DISORDERS | Bayer HealthCare AG (DE) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007042146-A1 | MICROANGIOPATHY TREATMENT AND PREVENTION | BAYER HEALTHCARE AG (DE) | 2007-04-19 | — | — | WO | disclosed |
| WO-2007039134-A1 | COMBINATION THERAPY COMPRISING SUBSTITUTED OXAZOLIDINONES FOR THE PREVENTION AND TREATMENT OF CEREBRAL CIRCULATORY DISORDERS | BAYER HEALTHCARE AG (DE) | 2007-04-12 | — | — | WO | disclosed |
| EP-1526132-A2 | Substituted oxazolidinone derivatives and their use as factor xa inhibitors | Bayer HealthCare AG (DE) | 2005-04-27 | — | — | EP | disclosed |
| EP-1261606-B1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | BAYER HEALTHCARE AG (DE) | 2005-02-23 | — | — | EP | disclosed |
| EP-1411932-A1 | SUBSTITUTED OXAZOLIDINONES FOR COMBINATIONAL THERAPY | Bayer HealthCare AG (DE) | 2004-04-28 | — | — | EP | disclosed |
| WO-2003000256-A1 | SUBSTITUTED OXAZOLIDINONES FOR COMBINATIONAL THERAPY | BAYER HEALTHCARE AG (DE) | 2003-01-03 | — | — | WO | disclosed |
| WO-2001047919-A9 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | BAYER AG (DE) | 2002-12-19 | — | — | WO | disclosed |